{
  "source": "MFN",
  "fetcher_build": "2026-08-03-nasdaq-fallback-calendar-v5",
  "status": "retrieved",
  "resolution": {
    "status": "resolved",
    "company_name": "MedCap",
    "expected_name": "MedCap",
    "match_score": 100.0,
    "slug": "medcap",
    "url": "https://mfn.se/all/a/medcap",
    "metadata": {
      "country": "Sverige",
      "list": "Mid Cap Stockholm",
      "sector": "Hälsovård",
      "industry": "Medicinteknik",
      "website": "https://mb.cision.com/Main/2678/4255245/3742455.pdf"
    },
    "ticker_candidates": [],
    "attempts": []
  },
  "releases": [
    {
      "source": "MFN",
      "fetcher_build": "2026-08-03-nasdaq-fallback-calendar-v5",
      "retrieved_at": "2026-08-04T14:20:57Z",
      "company": "MedCap",
      "issuer_match_score": 8.826446280991735,
      "title": "Strong organic and acquired growth; EBITA increased by 32%",
      "date": "2025-10-24",
      "report_type": "interim-report",
      "fiscal_year": 2025,
      "quarter": "q3",
      "period": "2025-q3",
      "report_key": "2025:q3",
      "release_url": "https://mfn.se/cis/a/medcap/strong-organic-and-acquired-growth-ebita-increased-by-32-8f9a71cb",
      "release_html_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-10-24-strong-organic-and-acquired-growth-ebita-inc\\release.html",
      "release_text_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-10-24-strong-organic-and-acquired-growth-ebita-inc\\release.txt",
      "attachments": [
        {
          "label": "MedCap_interim report_Q3 2025",
          "url": "https://mb.cision.com/Main/2678/4255245/3742455.pdf",
          "final_url": "https://mb.cision.com/Main/2678/4255245/3742455.pdf",
          "filename": "3742455.pdf",
          "local_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-10-24-strong-organic-and-acquired-growth-ebita-inc\\3742455.pdf",
          "content_type": "application/pdf",
          "size": 1282376,
          "sha256": "0c9bdbb9e12e0e7292955290ac9a7e69802f015fe65e3f559b2fda13c680c739",
          "extraction": {
            "source_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-10-24-strong-organic-and-acquired-growth-ebita-inc\\3742455.pdf",
            "filename": "3742455.pdf",
            "extension": ".pdf",
            "size": 1282376,
            "sha256": "0c9bdbb9e12e0e7292955290ac9a7e69802f015fe65e3f559b2fda13c680c739",
            "status": "extracted",
            "text_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-10-24-strong-organic-and-acquired-growth-ebita-inc\\extracted\\3742455\\3742455.txt",
            "text_chars": 62500,
            "metadata": {
              "page_count": 35,
              "empty_pages": 0,
              "encrypted": false
            },
            "children": [],
            "warnings": [],
            "manifest_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-10-24-strong-organic-and-acquired-growth-ebita-inc\\extracted\\3742455\\3742455.extraction.json"
          }
        }
      ],
      "status": "retrieved"
    },
    {
      "source": "MFN",
      "fetcher_build": "2026-08-03-nasdaq-fallback-calendar-v5",
      "retrieved_at": "2026-08-04T14:21:00Z",
      "company": "MedCap",
      "issuer_match_score": 8.840336134453782,
      "title": "7% tillväxt och EBITA marginalen återställd till 17%",
      "date": "2025-04-29",
      "report_type": "interim-report",
      "fiscal_year": 2025,
      "quarter": "q1",
      "period": "2025-q1",
      "report_key": "2025:q1",
      "release_url": "https://mfn.se/cis/a/medcap/7-tillvaxt-och-ebita-marginalen-aterstalld-till-17-2bf0a741",
      "release_html_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-04-29-7-tillvaxt-och-ebita-marginalen-aterstalld-t\\release.html",
      "release_text_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-04-29-7-tillvaxt-och-ebita-marginalen-aterstalld-t\\release.txt",
      "attachments": [
        {
          "label": "MedCap_delårsrapport Q1 2025",
          "url": "https://mb.cision.com/Main/2678/4141406/3415977.pdf",
          "final_url": "https://mb.cision.com/Main/2678/4141406/3415977.pdf",
          "filename": "3415977.pdf",
          "local_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-04-29-7-tillvaxt-och-ebita-marginalen-aterstalld-t\\3415977.pdf",
          "content_type": "application/pdf",
          "size": 1003735,
          "sha256": "0ac60857aaaa88e1159e6fdcdf3fea9f15d756add1aa0ad74717717301604157",
          "extraction": {
            "source_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-04-29-7-tillvaxt-och-ebita-marginalen-aterstalld-t\\3415977.pdf",
            "filename": "3415977.pdf",
            "extension": ".pdf",
            "size": 1003735,
            "sha256": "0ac60857aaaa88e1159e6fdcdf3fea9f15d756add1aa0ad74717717301604157",
            "status": "extracted",
            "text_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-04-29-7-tillvaxt-och-ebita-marginalen-aterstalld-t\\extracted\\3415977\\3415977.txt",
            "text_chars": 45278,
            "metadata": {
              "page_count": 32,
              "empty_pages": 0,
              "encrypted": false
            },
            "children": [],
            "warnings": [],
            "manifest_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\reports\\2025-04-29-7-tillvaxt-och-ebita-marginalen-aterstalld-t\\extracted\\3415977\\3415977.extraction.json"
          }
        }
      ],
      "status": "retrieved"
    }
  ],
  "skipped_because_nasdaq": [
    {
      "report_key": "2026:q2",
      "title": "Strong growth – adjusted EBITA increased by 28 percent",
      "date": "2026-07-21",
      "url": "https://mfn.se/a/medcap/strong-growth-adjusted-ebita-increased-by-28-percent"
    },
    {
      "report_key": "2026:q1",
      "title": "2026-04-29 06:30:00 Strong result; EBITA increased by 30% 478,00 SEK | +2,27% &nbsp| 14,5 MSEK",
      "date": "2026-04-29",
      "url": "https://storage.mfn.se/a/medcap/2b111a8d-cd97-4826-bd13-21156494687d/medcap-interim-report-q1-2026.pdf"
    },
    {
      "report_key": "2025:annual",
      "title": "MedCap publicerar årsredovisning för 2025",
      "date": "2026-03-23",
      "url": "https://mfn.se/a/medcap/medcap-publicerar-arsredovisning-for-2025"
    },
    {
      "report_key": "2025:q4",
      "title": "Strong results: EBITA increased by 68% for the quarter and 26% for the full year",
      "date": "2026-02-06",
      "url": "https://mfn.se/a/medcap/strong-results-ebita-increased-by-68-for-the-quarter-and-26-for-the-full-year"
    },
    {
      "report_key": "2025:q2",
      "title": "Starkt kvartal med 20 procent EBITA tillväxt samt förvärv inom Specialistläkemedel",
      "date": "2025-07-23",
      "url": "https://mfn.se/cis/a/medcap/starkt-kvartal-med-20-procent-ebita-tillvaxt-samt-forvarv-inom-specialistlakemedel-ee3c147d"
    },
    {
      "report_key": "2024:annual",
      "title": "MedCap publicerar årsredovisning för 2024",
      "date": "2025-03-27",
      "url": "https://mfn.se/cis/a/medcap/medcap-publicerar-arsredovisning-for-2024-cd04fbf9"
    },
    {
      "report_key": "2024:q4",
      "title": "God efterfrågan men otillfredsställande resultat. Starkt kassaflöde.",
      "date": "2025-01-31",
      "url": "https://mfn.se/cis/a/medcap/god-efterfragan-men-otillfredsstallande-resultat-starkt-kassaflode-3f4a778b"
    },
    {
      "report_key": "2025:q4",
      "title": "Preliminärt resultat för fjärde kvartalet",
      "date": "2025-01-16",
      "url": "https://mfn.se/cis/a/medcap/preliminart-resultat-for-fjarde-kvartalet-1aeb45d0"
    }
  ],
  "metadata": {
    "country": "Sverige",
    "list": "Mid Cap Stockholm",
    "sector": "Hälsovård",
    "industry": "Medicinteknik",
    "website": "https://mb.cision.com/Main/2678/4255245/3742455.pdf"
  },
  "ticker_candidates": [],
  "company_url": "https://mfn.se/all/a/medcap",
  "company_text_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\company.txt",
  "company_html_path": "D:\\Web\\aktieanalys\\data\\medcap\\mfn\\company.html"
}